Q&A: Promise and pitfalls of genome-wide association studies by Brookfield, John FY
Why do we need genome-wide association studies?
To  answer  that,  we  first  need  to  look  at  the  kinds  of 
genetic  changes  that  have  previously  been  studied  by 
medical geneticists. These have usually been ‘single-gene 
disorders’, which result from mutations in single genes, 
where an individual with a mutant allele of the gene (in 
the homozygous state for a recessive disorder) has the 
disease  with  a  hundred  percent  probability.  Thus,  an 
individual  homozygous  for  the  sickle-cell  allele  of  the 
beta-globin  gene  will  always  have  sickle-cell  anemia 
(Figure 1). When all individuals with the disease genotype 
have  the  disease,  we  describe  such  a  mutation  as  one 
hundred percent penetrant. When the penetrance is less, 
there  are  individuals  who  have  the  predisposing  geno-
type, but do not have the disease. This is because other 
genes play a role in the determination of the disease, or 
because of the effects of the environment. This makes the 
mapping of the gene causing the disease using pedigree 
information (as illustrated in Figure 1) more difficult.
Where  the  penetrance  is  very  low,  it  is  virtually 
impossible to map genes using pedigrees, and here we 
enter  the  world  of  multifactorial  disorders,  where  the 
presence or absence of the disease is influenced by many 
genetic differences and also by the environment. The role 
of  genes  in  determining  whether  individuals  have  the 
disease can still be important, and this is measured by the 
‘heritability’ of the disease, which is the proportion of the 
determination  of  the  disease  that  is  caused  by  genetic 
rather  than  environmental  differences.  Heritability  for 
such  disorders  is  measured  through  the  correlations 
between  relatives,  most  powerfully  using  monozygotic 
(identical)  and  dizygotic  twins.  Single-gene  disorders 
tend to be rare, whereas many important multifactorial 
diseases, including, for example, hypertension, diabetes 
and schizophrenia, have much higher frequencies in the 
population, but still have high heritabilities. The goal of 
genome-wide association studies (GWAS) is to understand 
common  multifactorial  diseases  and  the  genes  that 
predispose us to them.
Do common multifactorial diseases result from 
the combined effects of common alleles of 
predisposing genes?
That is indeed thought to be likely, and is the basis for the 
so-called  ‘common  disease-common  variant  model’  for  © 2010 BioMed Central Ltd
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Figure 1. Pedigrees. Here a square represents a male, and a circle 
a female. (a) For a dominant disorder, such as Huntington’s disease, 
represented by the allele symbol H, an individual need only inherit 
the mutant allele from one parent (that is, be heterozygous) to be 
affected. In such cases, affected individuals almost always are in 
fact heterozygous for the mutant allele, and they transmit it, and 
the disease, to half the offspring. (b) For a recessive disorder, in this 
case sickle cell anemia, shown by the β S allele symbol, the disease is 
seen only in individuals homozygous for the allele (that is, who have 
inherited the allele from both parents); they are typically the offspring 
of two heterozygotes (carriers of the disease).
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multifactorial diseases. The suggestion is that, since the 
disease is common, its presence may arise from a set of 
predisposing alleles at multiple loci, each of which is itself 
common in the population.
If an allele predisposes us to a disease, how does it 
become common? Why has selection not operated 
to eliminate it?
For single-gene disorders, we think of the frequency as 
typically  depending  on  a  ‘mutation-selection  balance’. 
Mutations at the disease locus arise all the time, and (in 
homozygotes  for  recessive  mutations,  or  heterozygotes 
for  dominant  mutations)  cause  disease.  The  disease 
lowers  an  individual’s  ability  to  survive  and  breed 
(Darwinian fitness), and mutations are eliminated from 
the  population  by  selection.  Eventually,  the  population 
reaches an equilibrium frequency of the disease, where 
the rate of loss of the disease alleles by selection is exactly 
balanced by the rate of gain of disease alleles by mutation. 
It follows that diseases with high mutation rates (such as 
Duchenne muscular dystrophy) are more common than 
diseases with lower mutation rates. Also, a disease that 
has a small effect on Darwinian fitness, such as one that 
has  its  effects  after  reproduction,  will  have  a  higher 
equilibrium frequency than a disease with a lethal effect 
in childhood. As I have said, single-gene disorders are 
rare:  the  mutation  rate  is  relatively  low,  and  selective 
pressure against them relatively strong.
Multifactorial diseases, by contrast, can be common, 
for  a  number  of  reasons.  First,  it  is  important  to 
remember  that  an  allele  that  predisposes  to  a  multi-
factorial disease is only affected by selection to the extent 
that the frequency of the disease is higher in individuals 
with that allele than in individuals lacking it, and if it has 
only a small effect on the probability of the disease, the 
selection against it is correspondingly reduced. There is 
also  a  difference  in  the  relevant  time  scale  for  multi-
factorial against single-gene disorders, which are typically 
caused by relatively recent mutations. A common allele 
predisposing  us  to  a  multifactorial  disease  could  have 
arisen tens or hundreds of thousands of years ago, and 
may  have  become  common  in  an  environment  that  is 
very different from that in which we now live. Perhaps 
the  selection  operating  at  that  time,  particularly  on 
diseases of old age, was very different from that prevailing 
now. There can also be gene-environment interactions, 
where an allele might produce a disease only in people 
living  in  a  modern  environment.  There  is  also  the 
possibility  that  the  allele  that  predisposes  to  a  disease 
may  have  other,  beneficial  effects.  (Such  an  allele  is 
described as ‘pleiotropic’.) The overall effect of the allele 
on fitness might then be very slight or could indeed be 
positive. Finally, the process of random genetic drift can 
raise the frequencies of alleles that predispose to disease, 
and  this  could  have  been  common  during  the  rapid 
increases in population size of modern humans as they 
spread  from  their  origins  in  Africa  during  the  last 
150,000 years.
How exactly can genome-wide association 
studies (GWAS) make it possible to identify the 
predisposing genes in multifactorial diseases? 
This  approach  is  driven  by  the  new  technologies  that 
allow tens or hundreds of thousands of polymorphisms, 
usually  single-nucleotide  polymorphisms  (SNPs),  to  be 
assessed simultaneously. This technique is applied to a 
set of cases (individuals with the disease) and a set of 
matched controls, and differences in the frequencies of 
SNPs between the two groups are assessed in order to 
identify SNPs that may be associated with the disease. 
With so many SNPs being tested, the situation is a bit 
tricky statistically as there is a danger of false positive 
associations - that is, associations that occur purely by 
chance and not because the SNP is linked to the disease. 
So, generally, the significance is adjusted on the basis of 
getting a ‘false discovery rate’ of 5% - that is, of all the 
SNPs  called  as  being  associated  with  the  disease,  it  is 
expected that only 5% will be truly unassociated SNPs 
showing an association by chance in the samples.
Wait! - What is a polymorphism? Is it a kind of 
mutation?
This  is  a  question  with  a  slightly  complex  answer. 
Population  geneticists  have  long  used  the  term  for 
genetic variation where, at a particular genetic locus, or, 
ultimately,  base  pair,  there  are  two  or  more  genetic 
variants  where  the  commonest  has  a  frequency  below 
around 95%. In other words, it is a situation where there 
is not a single normal (wild-type) allele with one or more 
rare variants - in which case the rare variant base pairs 
would  be  called  mutations.  What  makes  the  answer 
slightly complex is that there has recently and occasion-
ally been a subtle change in the use of the term. Thus, if, 
at a given base pair, 90% of alleles have a T and 10% have 
an A, we say that there is a SNP - a single nucleotide 
polymorphism  -  at  that  base.  However,  occasionally, 
some describe this in an asymmetrical way - in which the 
A is said to be a polymorphism and the T is not.
So the idea is that the SNPs identify predisposing 
alleles and thus the biological basis of the disease?
Ultimately, yes. But there are also practical benefits just 
to having a way of identifying individuals at risk without 
knowing the mechanism. For many multifactorial diseases, 
treatments and tests are available that are offered on the 
basis of calculated risk. Thus, a diagnostic test might be 
carried out on an individual whose lifestyle, age, family 
history  and  other  factors  added  up  to  a  22%  risk  of  a 
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condition,  but  such  a  test  might  not  be  offered  to 
someone with an 18% risk. The additional information 
about risk that is supplied by genotype can allow a more 
precise  targeting  of  tests  to  those  individuals  who  are 
truly most at risk.
One hope is that there could be different treatments for 
a  given  disease,  designed  for  those  with  differing 
underlying genetic causative factors. Thus, if one patient 
with a multifactorial disease has predisposing alleles A, C 
and E, while another patient with the same disease has 
predisposing alleles B, D and F, then it could be that the 
best drug treatments for these two patients are different 
even  though  their  symptoms  are  not,  because  of  the 
different  etiologies  of  their  diseases.  This  is  what  is 
known as personalized medicine.
But, more fundamentally, the identification of causative 
loci in GWAS can indeed give insight into the biology of 
the  disease.  An  allelic  difference  detected  in  GWAS 
might  only  have  a  weak  effect  on  the  probability  of 
getting the disease. But the modest effect seen may be 
slight not because the gene involved is unimportant in 
the pathway that leads to the disease, but because the 
alleles involved might both be functional alleles showing 
only subtle, quantitative differences in their action. The 
importance for treatment of the identification, through a 
disease association, of a gene or a pathway might well 
outstrip the importance of the effect of allelic differences 
at that gene on disease risk.
So are you implying that the SNPs associated 
with disease are directly causing defects in 
predisposing genes?
No. The simplest way in which a genetic variant, such as 
a SNP, can be associated with an increased risk of disease 
is indeed if such a variant directly causes the elevated 
risk. But it is much more likely, in any given case, that 
the  SNP  being  investigated  is  associated  with  other 
genetic differences which, in fact, determine the risk. In 
popu  lation  genetics  terms,  we  say  that  the  marker 
investigated  (in  this  case  the  SNP)  is  in  linkage 
disequilibrium  with  the  genes  causing  the  disease. 
Unfor  tunately,  because  of  the  ways  that  linkage 
disequilibrium can arise, this does not always help us to 
find the culprit gene.
So how does such linkage disequilibrium arise?
There  are  many  ways  in  which  this  can  happen.  One 
simple way is through population substructure. Thus, if a 
population  consisted  of  a  mixture  of  individuals  with 
African  and  European  ancestry,  for  example,  and  the 
disease  was  commoner  among  those  with  European 
ancestry, then, if one took a random sample of cases and 
a random sample of controls, the cases would be enriched 
for people with European ancestry, and all the SNPs that 
showed differences in frequency between Europeans and 
Africans would also differ between cases and controls, 
even though almost all would be unlinked to any genes 
actually causing the disease.
So does that mean that if you are looking at GWAS 
across populations, you are likely to be led astray 
by genetic differences between the different 
populations?
This is a danger, but it can be prevented, in principle, by 
matching the ancestry of cases and controls. Thus, each 
time you include an affected individual (a ‘case’) who has 
a particular ancestry, you add a control with a similar 
ancestry.  This  means  that  the  cases  and  controls  will 
come from the same mix of ethnic groups, and differ-
ences in the frequency of the disease between groups will 
not  create  false  positives.  Even  when  you  do  this, 
however, it is possible you may be led astray by cryptic 
population stratification.
What is cryptic population stratification?
While  it  could  be  straightforward  to  ensure  equal 
numbers  of  individuals  with  European  versus  African 
ancestry  in  the  cases  and  controls,  there  will  be 
subpopulations within these populations, which will be 
harder  to  match.  Any  SNP  that  shows  a  very  great 
frequency  variation  between  populations  is  at  risk  of 
being flagged up as being associated with a disease if the 
populations themselves show differing frequencies of the 
disease.
How else can linkage disequilibrium be generated?
Other  ways  in  which  linkage  disequilibrium  can  arise 
involve physical linkage, where the marker is found at a 
chromosomal  locus  that  is  near  the  genetic  difference 
actually causing the disease. This is the kind of linkage 
disequilibrium  that  GWAS  is  searching  for.  While 
linkage  disequilibrium  is  not  the  same  as  physical 
linkage,  variants  that  are  linked  in  the  sense  of  being 
close together on the chromosome are much more likely 
to be associated than are physically unlinked variants, 
because a chromosomal recombination event would be 
required  to  separate  them,  and  this  does  not  happen 
very often, especially if the SNP and the disease gene are 
very close to one another. New mutations can remain 
associated with physically linked variants for hundreds 
of generations.
So, if there is a strong association in a well matched 
sample between a SNP and the disease, the best guess is 
that there is a causative allele tightly linked physically to 
(and in linkage disequilibrium with) the SNP. The effect 
of the causative locus on the probability of getting the 
disease can be approximately estimated though the odds 
ratio associated with the SNP.
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What is an odds ratio?
The  odds  ratio  is  simply  the  probability  of  having  the 
disease given one genotype at a SNP (or other genetic 
variant) divided by the probability of having the disease 
given another genotype at the SNP. In a statistical sense, 
it is a measure of the effect size, rather than a significance 
value. So, as sample sizes go up, the odds ratios should 
become more accurate, and the evidence that odds ratios 
differ from one (with an odds ratio of one implying no 
genetic effect) should become more statistically signifi-
cant.  As  very  large  numbers  of  cases  and  controls  are 
now included in genome-wide association studies, more 
and more loci are found to show associations, and loci 
with low effect sizes (under 1.5) start to be detected with 
statistical confidence. Thus, for example, more than 30 
loci have been identified as being associated with risk of 
Crohn’s disease.
What is meant by the ‘missing heritability’ people 
seem to be talking about?
This is the mystery at the heart of results from genome-
wide association studies. Each of the SNP loci showing a 
disease association has a frequency in the population and 
a genetic effect (measured by the odds ratio). From the 
frequency of the marker and the effect size it is possible 
to calculate the contribution that this locus would make 
to the total genetic determination (the heritability) of the 
disease.  One  can  then  sum  the  effects  of  all  the  loci 
discovered,  to  assess  their  combined  genetic  influence. 
But, almost always, this genetic influence is much less 
than the influence measured by the heritability. The 32 
loci  shown  to  affect  Crohn’s  disease  risk  collectively 
explain only 20% of the heritability for the disease, for 
example. There must be some genetic explanation of the 
missing 80% of the heritability that is not being detected 
by the GWAS approach.
Where might the missing heritability be?
The GWAS methodology is designed to detect the effects 
of causative genetic loci where the rarer allele still has a 
reasonable frequency in the population (greater than 5%). 
If there are genetic loci influencing the trait where the 
rare allele has a frequency under 5%, or even under 1%, 
the GWAS technique is unlikely to be able to detect these 
loci. One idea about the cause of the missing heritability 
is that this is supplied by mutant alleles at very many loci, 
the majority of which are very rare. In a sense, we are 
back in the world of single-gene disorders, at least to the 
extent  that  the  individual  predisposing  loci  have  rare 
variants, created by fairly recent mutations and on the 
way  to  elimination  by  selection.  It  should  be  said  that 
another possibility is that there are many other loci with 
common causative alleles, but alleles with low odds ratios 
(that is, small effects), which will only be detected in even 
larger samples of cases and controls, and it is these that 
supply  the  missing  heritability.  There  will  also  be  an 
underestimation of the genetic effect of the known loci 
since they are represented by their surrogate linked SNPs, 
and  the  true  effects  of  the  causative  alleles  themselves 
could be greater.
So is this what is meant by genetic heterogeneity?
Yes, exactly. In general terms, genetic heterogeneity in 
disease causation means that the disease may be caused 
by  different  genes  in  different  individuals.  In  the  case 
discussed above, if there are very many loci that have rare 
alleles  that  are  causing  the  disease,  there  will  be  very 
great  differences  between  the  genotypes  of  affected 
individuals, and it will be hard to detect the individual 
causative loci.
But if the variants causing the disease are rare, why 
are the diseases common?
As I say above, fitness-lowering mutations at a locus in 
mutation-selection  balance  should  not  be  common, 
because selection is quantitatively stronger than muta-
tion. However, disease mutations are commoner in loci 
such as the dystrophin locus, which is very large and has 
a correspondingly high mutation rate, which explains the 
comparatively  high  incidence  of  Duchenne  muscular 
dystrophy.  There  is  only  one  gene  that  can  mutate  to 
alleles that cause Duchenne muscular dystrophy, but it 
may be that, for common multifactorial disorders, there 
are very many loci that can mutate to alleles that contri-
bute  to  producing  the  disease  symptoms.  So  the  total 
mutation rate for some conditions, such as schizophrenia, 
may be high because so many loci can mutate to pre-
disposing alleles. In effect, it is a question of target size.
What are the achievements of GWAS so far?
There  are  cases  of  important  causative  variants  being 
identified by GWAS. The GWAS approach is hypothesis-
free, in that it looks at very many SNPs simultaneously 
rather than focusing on loci whose biology suggests that 
a causal relationship to the disease is likely. The result of 
this is that, since each SNP tested constitutes a separate 
hypothesis test, very significant associations are needed 
in order to rule out false positives. Thus, sample sizes 
have to be large in order to find variants with low odds 
ratios.  However,  in  a  study  of  age-related  macular 
degenera  tion, a sample of only 96 cases and 50 controls 
identified  an  important  causative  variant  in  the 
complement  factor  H  gene.  Two  of  the  three  most 
significant associations came from SNPs in an intron of 
this locus and they were themselves significantly asso-
ciated with a tyrosine-histidine substitution encoded in 
exon 9 of the gene, which was inferred to be the causative 
SNP.  The  finding  of  the  causative  SNP  in  such  small 
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samples was due to the intronic SNPs initially identified 
having high odds ratios - 7.4 in one case when homo  zy-
gotes for a C base at the SNP were compared with other 
genotypes. The odds ratios were indeed so high that these 
intronic SNPs explained around half the total population 
risk. This case is unusual, in that a SNP with a massive 
effect  on  the  odds  ratio  nevertheless  showed  a  high 
population frequency for the disease-predisposing base. 
It could be that part of the cause is that the age of onset 
of the disease is one that would very rarely be attained by 
our  ancestors,  and  the  selection  on  the  condition  was 
probably  minimal  at  the  time  when  allelic  frequencies 
were being determined.
Where can I find out more?
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